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Functional Assessment for Acute 
Stroke Trials: Properties, Analysis, 
and Application
Martin Taylor-Rowan*, Alastair Wilson, Jesse Dawson and Terence J. Quinn
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
A measure of treatment effect is needed to assess the utility of any novel intervention in 
acute stroke. For a potentially disabling condition such as stroke, outcomes of interest 
should include some measure of functional recovery. There are many functional out-
come assessments that can be used after stroke. In this narrative review, we discuss 
exemplars of assessments that describe impairment, activity, participation, and quality 
of life. We will consider the psychometric properties of assessment scales in the context 
of stroke trials, focusing on validity, reliability, responsiveness, and feasibility. We will 
consider approaches to the analysis of functional outcome measures, including novel 
statistical approaches. Finally, we will discuss how advances in audiovisual and informa-
tion technology could further improve outcome assessment in trials.
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iNTRODUCTiON
Clinical trials are designed to assess the effect of a novel intervention versus a comparator. An arche-
typal stroke trial may, for example, assess the effect of endovascular treatment against a control of 
“usual care.” The PICO framework can be used to describe any clinical trial in terms of Population, 
Intervention, Control, and Outcome. While it is typically the intervention that attracts attention and 
represents the exciting new chapter in stroke care, we should not forget about the other components 
of a trial. In particular, outcome assessment in stroke trials is critical and the approach to outcome 
assessment can be the difference between a positive and neutral trial.
The outcome of any trial should provide some quantifiable measure of the effect of the treatment. 
Historically, endpoints such as mortality or event recurrence have been used in stroke trials. While 
useful, particularly for trials of primary and secondary prevention, these “hard clinical endpoints” do 
not capture the full extent of outcomes for a disabling condition such as stroke. Therefore, assessment 
of patients’ functional ability has been adopted and is now mandated by regulatory authorities for 
certain stroke trials. Multiple measures of post-stroke functional ability have been developed and 
many have been used in stroke trials.
In this review, commissioned as part of the themed series on hyper-acute stroke trials, we discuss 
commonly used functional outcome measures in these trials. We briefly describe their historical 
purpose before evaluating each in relation to core psychometric properties (see Table 1). We then 
discuss analytical approaches that can be used to assess stroke functional outcomes. Finally, we 
consider how training, structured assessment, and advances in technology may enhance stroke 
outcome assessment.
A FRAMewORK FOR CONSiDeRiNG OUTCOMe ASSeSSMeNT
There are numerous potential outcome assessments for stroke research (1). For example, even in 
a relatively niche area such as post-stroke psychological assessment, recent reviews have found 
TABle 1 | Core psychometric properties and how we evaluate them.
Psychometric property Domain and definition Statistical analysis
Validity: the degree to which a tool measures what it purports to measure Established via correlation e.g., Pearson’s “r” or Spearman’s “rho”:1.0 is a 
perfect correlation; 0.0 suggests no correlationConcurrent validity The extent to which a tool results correspond to other 
measures associated with the outcome of interests  
(i.e., functional disability)
Construct validity A tools association with other tools that measure the 
same, or a similar construct
Predictive validity Ability of the tool to predict future events Established via odds ratios (OR) e.g., OR:2.00 suggests two times greater 
odds of an outcome occurring when variable x is present than when not
Reliability: refers to a tools consistency in scoring over multiple assessments Established via kappa (k) or interclass correlation coefficient (ICC) values.
Both values range between 0 and 1 with values closer to 1 indicating  
greater reliability
Inter-rater reliability Consistency of scoring across different assessors
Intra-rater reliability Consistency of scoring within the same assessor
Internal consistency Agreement between items within a multiitem scale Established using Cronbach’s alpha
Responsiveness: the tools ability to detect meaningful change over time Determined based upon a tool’s sensitivity to improvement or decline with 
repeated testing
Feasibility: the practicality or reasonableness with which a tool can be used. Can 
incorporate measures of acceptability to rater and patient
Ratio or percentage of patients with which the assessment could be 
performed
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more outcomes than trials (2). With such a range of potential 
functional assessment tools, it is useful to have a framework 
for considering the application of these tests. Our goal is 
functional outcome assessment, but “functional outcome” is a 
broad term that encompasses many constructs. A potentially 
useful way to categorize functional outcomes is to consider 
the World Health Organization International Classification of 
Function (WHO-ICF). The WHO-ICF describes function in 
terms of impairment, activity (formerly disability), participa-
tion (formerly handicap) (3), and we could add a fourth level 
of quality of life (QOL). Stroke assessment scales are available 
to describe functional outcome at each level of the WHO-ICF 
(Figure 1).
Even within each level of WHO-ICF, there can be many poten-
tial assessments to choose from. The science of psychometrics 
(sometimes called clinimetrics in the applied clinical context) 
describes properties of assessment scales. The classical proper-
ties that are important for a clinical assessment tool are validity, 
reliability, responsiveness to change, and feasibility/acceptability 
(4). Depending on the clinical context and population to be 
studied, some psychometric properties may be more important 
than others (Figure 2).
We will consider three outcome assessment scales that have 
been frequently used in acute stroke trials, each one has been 
chosen as an exemplar of a certain level of the original WHO-ICF 
framework. For each assessment scale, we will describe all four of 
the classical psychometric properties, using each scale to major 
on a particular aspect relevant to that scale.
Research into the properties of stroke scales is an evolving 
field. In this review, we highlight many of the seminal papers 
that have influenced our understanding of stroke clinimetrics. 
We recognize that in some instances authors may have used sta-
tistical approaches that are not reflective of current best practice. 
For example, statistical analyses based on parametric assump-
tions have often been applied to stroke scales that are ordinal 
or nominal in structure. While some argue that parametric 
statistics are inappropriate for evaluating stroke scales, it would 
be wrong to ignore all the available research that has used this 
approach. We also note that variations in language and transla-
tions can potentially affect scale properties. Our discussion will 
predominantly focus on the original (English language) versions 
of these tools.
iMPAiRMeNT: NATiONAl iNSTiTUTeS OF 
HeAlTH STROKe SCAle
History and Purpose
The NIHSS was specifically designed for assessment of interventions 
in clinical trials. Of key intent was that the tool should be employed 
easily and quickly at the patient bedside to enable practicality of 
use (5). Rather than measuring function specifically, the NIHSS 
operates a 15-item ordinal, non-linear, neurological impairment 
scale covering consciousness, ocular movement, vision, coordina-
tion, speech and language, sensory function, upper and lower 
limb strength, facial muscle function, and hemi-neglect (6). Initial 
piloting took place in a controlled acute stroke trial assessing the 
effects of naloxone; it is now commonly used in acute-clinical 
stroke practice (see Table S1 in Supplementary Material).
validity
The NIHSS’ attention to specific neurological deficits engenders 
a high-concurrent validity (0.4–0.8) based upon association with 
infarct size (5, 7). Information on construct validity is lacking. The 
tool is well suited to early stroke severity assessment and baseline 
scores have strong predictive validity with outcome at 7 days and 
3 months (8). Specifically, patients with a baseline score of <5 are 
almost always (80%) discharged home; scores of 6–13 often need 
inpatient rehabilitation; and scores of 14+ are strongly associated 
with need for longer-term care.
There are however questions as to how well the tool deter-
mines “real world” functional impact. For example, a lesion that 
FiGURe 1 | World Health Organization International Classification of Function (WHO-ICF) Assessment Scales.
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results in a hemianopia and a score of “1” on the NIHSS would 
typically be categorized as a “good” outcome (9). Yet, if such 
impairment precludes driving, consequences upon employment, 
independence and mood could be substantial. Additionally, the 
focus of the tool is weighted toward limb and speech impairments 
with reduced attention to cranial nerve-related lesions (10) and 
appears to have reduced validity when lesions present in the non-
dominant hemisphere (11).
Reliability
The scale has exhibited excellent inter (ICC =  0.95) and intra-
observer reliability (ICC = 0.93). The high inter-rater reliability is 
observed in both neurologically trained and non-neurologically 
trained raters alike (11).
Responsiveness
The responsiveness of the tool has compared favorably to both the 
BI and mRS in detecting a treatment effect (5, 9).
Feasibility
The NIHSS is optimally generated using a formal observational 
patient assessment. Recognizing that unwell patients may be 
unable to participate in all aspects of testing, there is scor-
ing guidance for incomplete test items. On average, NIHSS 
assessment takes around 5 min to complete. For retrospective 
assessment in audit or research, the NIHSS can be derived using 
medical records (12); this is not true for more complex assess-
ments such as mRS (13).
FiGURe 2 | Functional scale psychometric properties.
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Summary
The NIHSS has favorable properties, although as an impairment-
based scale it is not a good measure of the broader disability 
that can result from a stroke. The NIHSS is perhaps best used 
as case-mix adjuster or early outcome assessment measure for 
hyper-acute trials.
ACTiviTY: BARTHel iNDeX
History and Purpose
Designed to measure independence, the Barthel index (BI) was 
originally used to assist patient discharge and long-term care 
planning in non-stroke settings (11). The BI operates according 
to a 10-item scale in which patients are judged upon degree of 
assistance required when carrying out a range of basic activities 
of daily living (ADL) (see Table S1 in Supplementary Material). 
The assessment is delivered through an established and validated 
questionnaire comprising a total score of 100 for the 10 items of 
the scale. The patient’s answers on each item are scored based 
upon actual ability (preferably observed by the assessor). The 
usual scoring for each item is 0 points for “no ability” to do the 
item independently, 5 points for “moderate help” with the item, 
and 10 points for being able to manage the item independently. 
The BI has emerged as the second most popular tool for assess-
ment of post-stroke outcome in clinical stroke trials (1).
validity
Concurrent validity, appropriated via correlation with infarct 
size, extent of motor loss and nursing-time requirements, appears 
to be moderate (r2 =  0.3–0.5) (7, 14, 15). Construct validity is 
favorable when compared with other measures of activity (16), 
while predictive validity of the BI has been established on basis 
of low BI scores correlating with future disability, longer time to 
recovery, and heightened care needs (17). It is important to note, 
however, that the predictive validity of the BI can be suboptimal 
if it is conducted too early (within 5 days post-stroke) (18), and 
validity of the tool may be compromised by self-report measure-
ment, particularly when cognitive impairment is present (19). 
Validity of the tool when used in the hyper-acute stroke period is 
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also questionable as monitoring equipment, physical illness, and 
restrictions on mobility may all compromise the true score.
Reliability
The inter and intra-reliability of the tool is judged to be moderate 
(k = 0.41–0.6) to high (k = 0.81–1.00) (20, 21). However, the stud-
ies from which this evidence pertains are limited in sample size 
and heterogeneous in both methodology and assessment quality 
(18). Of additional note, reliability seems to vary across specific 
items of the scale and is greatest at higher BI scores (22).
Responsiveness
Responsiveness to change has been described as a strength of the BI 
over other stroke functional assessment tools (23–25). The overall 
responsiveness of the tool is reasonable within a certain range of 
disability; however, it also appears vulnerable to floor and ceiling 
effects, which are largely attributable to the scales’ assessment of 
basic ADLs only (11). Specifically, the tool is often insensitive to 
changes in patients whose general mobility and physical function 
is impaired, but who improve in other aspects—for example, cog-
nitively (floor effect); or where there are limitations in extended 
ADL’s—for example, due to cognitive impairment (ceiling effect).
Feasibility
The simple structure of the BI allows for direct assessment, 
proxy-based assessment, telephone assessment, and postal ques-
tionnaire. Where possible the information should be based on 
direct observation of the tasks. BI is relatively quick to perform, 
but for large-scale audit and research shorter versions have 
been developed. Recent efforts to enhance feasibility include a 
short-form version of the BI which includes three items: bladder 
control, mobility, and transfers (26). This version of the tool has 
been validated via systematic review of short-form BIs, and while 
validity is reduced by comparison to the full scale, it is no worse 
than longer versions containing four and five items (27).
Summary
Although still a popular outcome measure, the BI has properties 
that limit its utility as primary endpoint in an acute stroke trial. In 
particular, for those trials where moderate-to-severe disability is 
not expected, the usefulness of BI is limited by an emphasis on basic 
ADLs and physical constructs. The BI is perhaps best used to assess 
case-mix and early outcomes in stroke rehabilitation settings.
PARTiCiPATiON: MODiFieD RANKiN 
SCAle
History and Purpose
Adapted from the original 1957 Rankin scale (28), which was 
designed to assess patient outcomes in one of the first stroke 
units, the modified Rankin scale (mRs) was the first functional 
outcome assessment used in a stroke trial. The mRS is the 
most commonly used functional assessment measure and is 
recommend by professional societies and regulatory bodies1 for 
1 https://www.commondataelements.ninds.nih.gov/Doc/NOC/Modified_Rankin_
Scale_NOC_Public_Domain.pdf (Accessed: November 30, 2017).
outcomes assessment in stroke trials. The mRS adopts a 7-point 
hierarchical, ordinal scale to measure functional independence 
(see Table S1 in Supplementary Material).
There has been some debate as to the nature of mRS scoring. 
We have classified as a measure of participation for the purpose 
of this review, as the scale offers a broad focus potentially going 
beyond the basic and extended ADL measures of an activity 
scale. Other scales are available that are more clearly aligned with 
the concept of participation but these tools are rarely used in 
stroke trials (29) whereas mRS is a common outcome assessment 
that at least serves as a proxy of participation.
validity
Analysis of clinical properties suggests concurrent validity 
based on correlation coefficients with infarct volume is of 
0.4–0.5 (30)—comparable to the BI (14, 15, 31). Assessment 
of construct validity suggests that the mRS has excellent agree-
ment with other stroke functional scales (32), while predictive 
validity is demonstrated by the association of short to medium 
term mRS with longer-term post-stroke care needs (17). The 
validity of the scale can however be affected when a proxy is 
used to generate a score, or when applied in the acute setting 
during when the patient has not yet had the chance to resume 
normal activities. When used in a retrospective fashion to 
determine the pre-stroke functional state, the mRS validity can 
be diminished, demonstrating moderate-concurrent validity 
(ρ > 0.4) when compared with other variables associated with 
function (33).
Reliability
Reliability, particularly inter-observer variability, has been identi-
fied as the main drawback of the scale. This is a consequence of 
the simplicity of the tool and its use of a 7-point scale, which is 
both shorter than many other assessments and less categorical in 
descriptors at each point, thus requiring greater interpretation 
from assessors (34). Meta-analysis suggests an inter-rater reli-
ability of κ = 0.62; however, in multicenter trials this maybe be 
as low as κ = 0.25 (35). This can be further compromised when 
telephone assessments are utilized to conduct the assessment 
(36). Statistical noise generated by the poor inter-rater reliability 
of the mRS increases vulnerability to type-2 errors, meaning that 
clinically significant treatment effects can be missed. Some of 
these issues can however be potentially alleviated via structured 
interview, training and central adjudication, all of which we 
discuss below (37–39).
Responsiveness
The mRS responsiveness to change has received comparatively less 
attention than the scales’ other properties. With a limited number 
of possible scores, the mRS may have inferior responsiveness to 
change compared with other measures of post-stroke function, 
although any change seen in the mRS is likely to be clinically 
meaningful. In a non-random sample of stroke rehab patients, 
the BI has demonstrated favorable responsiveness to change 
over the mRS (p = 0.002) (23). Further issues with regard to the 
responsiveness of the mRS over particularly short time-frames 
(i.e., admission to discharge) have also been highlighted (23).
6Taylor-Rowan et al. Stroke Functional Assessment Review
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Feasibility
The traditional method for mRS assessment is an unstructured 
direct to patient interview. These interviews are usually short, 
but the open nature of mRS questions can lead to longer inter-
views while issues are explored to the satisfaction of the assessor. 
Where a patient is unable to fully participate in an interview, a 
proxy can be used (40). The use of structured interviews may 
improve reliability, although this has not been consistently 
proven, and short structured mRS assessments have been used 
in some trials (41).
Summary
Overall, the mRS offers a brief yet broad ranging assessment of 
function. This comes at the price of reliability issues and potentially 
reduced responsiveness to subtle improvement or deterioration. 
As a global measure of functional recovery that captures clinically 
meaningful change, mRS is perhaps best suited as endpoint in 
large trials of potential stroke treatments.
QUAliTY OF liFe
Moving beyond the WHO-ICF construct of participation, one 
can consider a further level of potential outcome assessment as 
QOL. Again, there are various QOL tools available; for clinical 
purposes we usually consider health-related assessment scales 
(HR-QOL) and these can be generic (e.g., the various iterations of 
the Euro-QOL) or stroke specific (e.g., the Stroke Impact Scale). 
QOL assessments have particular utility as they can be used 
to inform health economic analyses (42). The use of HR-QOL 
assessments is increasing, in part driven by the recognition of the 
value of patient reported outcome measures. At time of writing 
no positive stroke trial has used an HR-QOL as primary outcome 
but this may soon change. In the longer-term post-stroke, QOL 
will be a product of many factors many of which may be unre-
lated to the stroke. There is a tension between having a tool that 
allows comprehensive assessment and having a tool that does 
not require a lengthy and burdensome interview. In this regard, 
recent attempts to create shorter HR-QOL forms that retain the 
most discriminating questions are welcome (43).
STATiSTiCAl ANAlYSiS OF FUNCTiONAl 
eNDPOiNTS
The statistical approach to analysis of functional outcomes can 
have implications for sample size, validity and ultimately the suc-
cess of the trial. In this section, we will mostly discuss the mRS 
but many of the themes regarding analysis will equally apply to 
other assessment scales.
Composite endpoints
So far we have considered functional assessment scales in isola-
tion. However, as the scales assess differing constructs there could 
be advantage in combining endpoints. Indeed in the seminal 
NINDS trial of tPA, scores on NIHSS, BI, mRS, and Glasgow 
Outcome Scale were assessed in aggregate. The use of composites 
may have particular utility where outcomes individually may 
be uncommon. Using a modeling approach, the utility of a 
composite outcomes to improve power in a trial in minor stroke 
and acute ischemic stroke have been described (44). The main 
limitation of composites is in the interpretation and there can be 
problems, if, for example, a patient has a favorable outcome on 
one component of the composite and an unfavorable outcome on 
another. Also, if measures are not independent of one another, 
error measurement can be exacerbated and there can be a tempta-
tion to adopt this approach post hoc because individual measures 
are non-significant (45).
Cut Points and Shift
The mRS offers ordinal, hierarchical data, and historically the 
most commonly applied approach to analyses was to dichotomize 
scales at a set cutoff point, thus distinguishing those who achieve 
a “good outcome” from those who do not. Although there have 
been attempts to define an optimal cut point for the differing 
outcome assessments (9, 46), this approach is slightly misleading 
as the optimal cut point will vary with the population studied and 
the anticipation of functional recovery. So, for example, in studies 
of decompressive hemicraniectomy, a “good” outcome could be 
defined as less than or equal to mRS 3, while in a trial of tPA 
for minor stroke one would define a good outcome at a much 
narrower range, for example, mRS 0–1. What is clear from all the 
studies of dichotomized cut points is that the choice of scale and 
cut point will dictate the required sample size to demonstrate a 
treatment effect.
Dichotomization offers relatively simple comparative analy-
ses, but this reductionist good versus bad outcome approach can 
miss important treatment effects and will be insensitive to partial, 
but meaningful improvements in functioning, such as an increase 
from a score of 5 to 3 in the mRS (i.e., an improvement from 
bed-ridden to independent mobility, a change which most would 
accept as clinically important). Indeed, adoption of a dichoto-
mization approach has been implicated in false-neutral findings 
of stroke trials with examples of trials where dichotomized 
outcomes potentially missed a treatment effect that was observed 
using other approaches and examples of where dichotomized 
outcomes may have provided missed potentially harmful inter-
ventions (47).
It is possible to apply a prognosis adjusted endpoint method 
to analyses, whereby “good” outcomes are defined by achieving a 
standard dichotomized “good outcome” or by extent of improve-
ment across the scale (e.g., an improvement in score of n points 
on NIHSS). This moderates some of the statistical limitations 
inherent to dichotomization as it allows more patients’ data 
to contribute to the results (9). Again, however, there is some 
uncertainty as to how such “good outcomes” should be defined 
regarding the extent of change in score. Research into the NIHSS 
suggests the most discriminating prognosis adjusted endpoint 
appears to be a score of 1 or less overall, or a change in score of 
11 points (9).
The alternative approach to segregating data and analyzing 
on the basis of dichotomized “good outcomes” is to evaluate 
more of the scale. Trichotomized endpoint analyses have been 
described but have been superseded by techniques that allow 
assessment of the entire ordinal scale range via a shift analysis. 
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Such approaches that exploit the full distribution of outcomes 
include the proportional odds model and the Cochran–Mantel–
Haenszel test. Shift analysis has been suggested to improve the 
overall power that can be generated compared with a dichoto-
mized mRS (47). This seems to be particularly true when treat-
ment effects are small, but uniform over all respective ranges of 
stroke severity (although dichotomization can be mildly more 
powerful than shift analysis when treatment effects are sub-
stantial in certain circumstances) (47). The potential utility of 
the shift analysis over dichotomization has been demonstrated 
empirically in recent trials. For example, the INTERACT-2 
study of blood pressure reduction in intracerebral hemorrhage 
was neutral on a primary endpoint of dichotomized mRS, but 
demonstrated a treatment effect on prespecified secondary shift 
analyses (48).
A shift approach to mRS assessment is gaining traction in 
stroke research but we must be mindful of potential limitations 
in this approach. The main issue with this method is that there 
are implicit assumptions inherent to shift analysis that may 
not hold when applied to ordinal scales such as the mRS. For 
example, the Cochran–Mantel–Haenszel method of analysis 
assumes that treatment effects are uniform over the full range 
of the mRS scale; that is, that the treatment effects will be the 
same for those scoring mRS 0–1 as it is for those scoring mRS 
2–3 (49, 50). Moreover, shift analysis is typically considered 
superior to dichotomized analysis when the error is uniform 
across the scale. However, inter-rater reliability and misclas-
sification errors are often most problematic in the mid-range 
(mRS 2–4) of the mRS scale, meaning that errors are typically 
not evenly distributed (51). When error rates are high and 
non-uniform, shift analysis may reduce power by comparison 
to dichotomization (52). Due to these issues, some authors (45, 
52, 53) advise against employing shift analysis to ordinal scales 
such as the mRS, particularly in early-phase trials with small 
patient samples.
Utility weighting
A novel approach to assessment that has been used in contem-
porary endovascular studies is to apply weighting to outcomes. 
In utility weighting, it is recognized that certain health outcomes 
and transitions between outcomes will be more desirable than 
others. A utility weighted mRS has been developed that incor-
porates patient and societal valuations of each potential mRS 
outcome (54). The weighting can be performed by mapping 
EQ-5D population data onto mRS or using disability weighting. 
Potential advantages of utility weighted mRS have been demon-
strated using secondary analysis of existing trial data (54) but 
the real proof of the value of the utility weighted approach comes 
from the recent DAWN trial (55). As the greatest utility values are 
assigned to transitions from high disability states to lower, then 
the utility-based approach may have particular value in treat-
ments with the potential to prevent disability such as large artery 
thrombectomy. It is however important to note that in adopting 
this approach the higher ends of the mRS scale are filtered out, 
which may produce a non-Gaussian distribution. Hence, this 
method can result in the inappropriate application of standard 
statistical tests.
FUTURe DiReCTiONS iN STROKe 
OUTCOMe ASSeSSMeNT
Even with an appropriate outcome measure and statistical analysis 
plan, demonstrating a treatment effect of a stroke intervention is 
not easy. Developments in audiovisual and information technol-
ogy and best practice guidance in outcome assessment is helping 
to raise standards and improve the application of stroke outcome 
assessments.
Training
Although the assessment scales discussed are theoretically objec-
tive, there is always a degree of subjective interpretation. To ensure 
standardization of assessment, scoring rules and training materi-
als have been developed. Direct training from an experienced 
assessor is not possible at scale across the many international sites 
that may participate in a stroke RCT. Training manuals and use of 
audiovisual materials is one potential solution. For example, mass 
training in NIHSS using video-recorded patient assessments has 
proven feasible and popular (56). The format has evolved with 
changes in available technology from videotape recordings (57), 
to DVD and now interactive online materials (58). Completion of 
NIHSS training has been shown to improve scoring and a certifi-
cate of completion of NIHSS training is now mandatory for many 
studies where NIHSS is an outcome measure. Similar resources 
are available for mRS (59) and BI and also seem to improve 
application of these scales (60). The mRS training is similar to 
NIHSS with teaching cases, tutorials, and a certification exam.2 BI 
training is a descriptive tutorial rather than video-based patient 
assessment (see text footnote 2). Although the use of these mRS 
and BI training materials seems intuitively attractive, there have 
been no suitably large trials that have demonstrated improve-
ments in scoring with training. Nonetheless, it seems unlikely 
that training would worsen performance in assessment and so 
we would advocate continued use of such resources.
Structured Assessments
The mRS and to a lesser extent the BI are based on an interview 
with the patient. To ensure interviews are focused and have 
consistency of content, a series of structured mRS’ have been 
proposed. These can be structured, anchoring questions with 
guidance on interpretation or more formal questionnaires with a 
series of yes/no responses. Advocates of the structured approach 
report less time spent on interview and improved reliability. 
However, proponents of a less-structured interview note the 
benefits of a flexible approach. A structured interview can result 
in the discarding of essential information when contemplating a 
patient’s functional ability, particularly concerning usual activi-
ties such as work or hobbies. Moreover, if a patient’s answers do 
not “fit nicely” with a given item in the questionnaire, the rigid 
structured nature of the interview can be a hindrance rather than 
a benefit. A systematic review and meta-analysis that pooled all 
available data did not find benefits of structured interview over 
2 https://secure.trainingcampus.net/uas/modules/trees/windex.aspx?rx=rankin-
english.trainingcampus.net (Accessed: November 30, 2017).
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standard face-to-face interview, albeit some of the structured 
interviews used in contemporary trials were not available at the 
time of the review (61).
Centralized Adjudication
Expert group adjudication of outcome measures such as neuro-
imaging or electrocardiographs (ECG) has been routinely used in 
multicenter clinical trials as a method of reducing inter-observer 
variability and maintaining quality control. In contrast, tradition-
ally functional outcomes were only assessed at participating sites, 
but the landscape is changing.
As mRS and to a lesser extent BI can be scored based on an 
interview, both have the potential for telephone administration. 
The properties of telephone mRS and BI are less well described 
than direct assessment and there may be some systematic differ-
ences in scoring. However, telephone assessment is attractive for 
a large multisite study, as it saves time, reduces patient/assessor 
travel and reduces test burden. In terms of centralized assess-
ment, if telephone interviews are coordinated from a single center 
there can be more consistency of assessment and easier quality 
control. Telephone assessments can be audio recorded for off-line 
assessment by an adjudication panel. These processes were used 
for a subset of assessments in a recent thrombectomy trial (62).
Audio recording only gives a partial assessment and with the 
increasing availability of affordable portal video-recording equip-
ment and high-speed data transfer there is increasing potential 
for audiovisual recording of stroke assessment. Such video assess-
ment allows for remote centralized adjudication of any functional 
outcome assessment.
Centralized adjudication of the mRS has been employed in 
international trials with recruitment from a diverse range of 
countries from Vietnam to Kazakhstan and both North and South 
America (37). In this particular video-based platform, typically, 
the centralized adjudication of Rankin scoring employs a panel of 
2 or more raters from a pool of expert assessors to score the mRS 
of the patient. A final score is assigned by a committee based on 
consensus agreement.
While video-based centralized adjudication necessitates an 
additional initial cost to the trialists, the availability of low-cost 
video-recording equipment and high-speed data transfer will 
mean that any initial outlay will be modest. The benefits gained 
from source data validation for the patients’ existence and con-
sent as well as more stringent blinding to treatment and quality 
control of the assessment all add value and likely become cost 
effective in medium- to large-scale trials.
Furthermore, although the approach is still evolving, the use 
of centralized adjudication begets improvements in inter-rater 
reliability. Evidence to date suggests that centralized adjudication 
of the mRS can improve the inter-rater variability in multicenter 
trials from κ = 0.25 to 0.59 with an ICC = 0.87 for one rater and 
predicted to be 0.92 with four raters (37). This improvement in 
reliability can have a modest effect in the reduction of sample size 
required to see treatment effect. With the high per-patient cost in 
clinical trials, any potential reduction in patient numbers without 
sacrificing trial power is of benefit to trialists.
CONClUSiON
There are many functional assessment scales available for use in 
stroke trials. It is possible that previous inappropriate choice of 
functional outcome assessment may have caused us to miss potential 
treatment effects in stroke trials. With some thought on the aspect 
of function of greatest interest (impairment, activity, participation), 
the preferred psychometric properties, and the proposed analyti-
cal technique, the researcher can make an informed choice as to 
the optimal outcome assessment for their study. The use of novel 
statistical techniques, rater training, and central adjudication have 
all been proven to improve the utility of outcomes assessments.
The stroke community has made substantial progress in 
outcome assessment methodology, but there is still more to 
do. The outcomes described are poor measures of cognitive 
and psychological outcomes and yet these are the outcomes of 
most importance to patients. As we make greater use of “big 
data,” for example, national registers, we need methods to 
incorporate feasible but valid outcome assessment into routine 
data collection.
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